Liminatus Pharma to Acquire InnocsAI in $320 Million Deal, Gaining Next-Generation CAR-T Pipeline for Hematologic and Solid Tumors
核心洞察
Liminatus Pharma (搜索) has entered into a definitive merger agreement with InnocsAI (搜索), an oncology-focused biotech developing advanced CAR-T and antibody-based therapies, in a deal valued at approximately $320 million.
The acquisition brings a portfolio of cell therapy assets including IBC101 (搜索), a Phase 1/2a-ready CD19xCD22 bivalent CAR-T for relapsed/refractory B-cell malignancies, and INC101, a preclinical dual-antigen CAR-T for solid tumors.
The amended agreement allows the merger to close on July 2, 2026, prior to stockholder approval, with InnocsAI (搜索) holders receiving common stock, non-voting convertible preferred stock, and contingent value rights.
Liminatus Pharma (搜索), Inc. announced on May 21, 2026, that it has entered into a definitive merger agreement with InnocsAI (搜索) LLC, a biotechnology company focused on advanced CAR-T and antibody-based oncology therapies. The transaction, valued at approximately $320 million, is designed to expand Liminatus' oncology pipeline with multiple biologic and cellular therapy assets targeting significant challenges in hematologic cancers and solid tumors. The agreement was subsequently amended and restated, with closing now expected on July 2, 2026, subject to customary closing conditions.
"This proposed transaction represents a transformational opportunity for Liminatus to expand into next-generation oncology cell therapies," said Chris Kim, Chief Executive Officer of Liminatus Pharma (搜索). "InnocsAI (搜索)'s portfolio includes differentiated CAR-T technologies designed to address major limitations in current cancer therapies, including antigen escape, tumor heterogeneity, and the immunosuppressive tumor microenvironment."
Transaction Structure and Terms
Under the amended terms of the merger agreement, InnocsAI (搜索) will merge with and into a newly formed wholly owned Delaware subsidiary of Liminatus. The existing members of InnocsAI will receive aggregate consideration consisting of 1.6 billion shares of Liminatus common stock at an issue price of $0.20 per share, along with contingent value rights representing the right to receive 20% of future net proceeds from certain strategic transactions involving the acquired assets.
The restructuring allows the merger to close prior to obtaining stockholder approval. InnocsAI (搜索) equity holders will be issued Liminatus common shares up to the maximum allowed without prior stockholder approval under Nasdaq rules, estimated at 19.99% of outstanding shares immediately before closing. The remainder will be issued as non-voting convertible preferred stock, which can only be converted into common shares once stockholder approval is obtained.
IBC101 (搜索): Bivalent CAR-T for B-Cell Malignancies
The lead clinical asset in the acquired portfolio is IBC101 (搜索), an autologous CD19xCD22 bivalent CAR-T cell therapy candidate designed for relapsed or refractory B-cell malignancies. The product functions as an OR-gate CAR-T therapy, enabling recognition of malignant B cells expressing either CD19 (搜索) or CD22 (搜索).
IBC101 (搜索) has received authorization from the Ministry of Food and Drug Safety of the Republic of Korea for a Phase 1/2a clinical study in relapsed or refractory diffuse large B-cell lymphoma (搜索) (DLBCL), with Seoul St. Mary's Hospital identified as the lead clinical site.
The dual-targeting design is intended to address antigen escape and tumor heterogeneity, which are recognized mechanisms of relapse following single-antigen CD19 (搜索)-directed CAR-T therapy. The construct also incorporates an ex vivo expansion process using IL-7 and IL-15, aimed at supporting T-cell fitness and persistence.
INC101: Dual-Antigen CAR-T for Solid Tumors
INC101 is a preclinical autologous bicistronic CAR-T cell therapy candidate for solid tumors based on a dual-antigen MSLNxCD276 design. The construct functions as an AND-gate system in which mesothelin provides the primary tumor-associated activation signal and CD276 (搜索) (B7-H3 (搜索)) provides a secondary costimulatory signal. This design is intended to improve tumor selectivity by requiring convergence of two tumor-associated signals.
The program is designed to address challenges that have limited CAR-T development in solid tumors, including on-target/off-tumor risk, antigen heterogeneity, tonic signaling, T-cell exhaustion, and tumor microenvironment-mediated suppression. A related follow-on construct, INC102 (搜索), incorporates a dominant-negative TGF-β receptor armoring strategy intended to support T-cell function in TGF-β-rich tumor microenvironments.
The proposed development focus includes biomarker-selected solid tumors with mesothelin and CD276 (搜索) expression, including malignant pleural mesothelioma (搜索), ovarian cancer (搜索), pancreatic cancer (搜索), and other selected solid tumors.
CS1 Antibody Platform and Trivalent Strategy
The CS1 antibody platform consists of proprietary anti-CS1 monoclonal antibodies intended to serve as an enabling module for Liminatus' hematologic CAR-T platform. Rather than a standalone CS1-directed CAR-T program, the CS1 binders are designed to be combined with the CD19xCD22 bivalent CAR-T backbone to support development of a potential CD19xCD22xCS1 trivalent CAR-T candidate.
This strategy aims to extend the platform from B-cell malignancies into plasma-cell malignancies, including multiple myeloma (搜索). CD19 (搜索) and CD22 (搜索) provide coverage of B-cell leukemias and lymphomas, while CS1 adds plasma-cell targeting capability.
Strategic Rationale
"This merger represents a transformational step in Liminatus' strategy to build a diversified oncology biotechnology company," Kim stated, adding that InnocsAI (搜索)'s cell therapy platform complements Liminatus' immuno-oncology programs and broadens its pipeline, creating multiple opportunities for long-term shareholder value.
The proposed merger has been approved by the boards of directors and managers of both companies and remains subject to customary closing conditions, including shareholder approval and regulatory approvals. Additional information will be included in a Current Report on Form 8-K to be filed with the U.S. Securities and Exchange Commission.